Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 3 8Phase 1/2 5Phase 1 4Phase 2/3 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Lymphoid 1Gynecologic 1Breast 1

Conditions

Prostatic Neoplasms 25Lymphoma, Large B-Cell, Diffuse 23Burkitt Lymphoma 16Lymphoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Non-Hodgkin 9Lymphoma, Follicular 9Neoplasm Metastasis 7Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 6Lymphoma, B-Cell 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Multiple Myeloma 5Lymphoma, T-Cell, Peripheral 5Leukemia 5Recurrence 4Neoplasms 4Lymphoma, T-Cell 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 4Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Carcinoma, Non-Small-Cell Lung 3Thrombocythemia, Essential 2Primary Myelofibrosis 2

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × Prednisone × Clear all
NCT01695005 2025-12-26

A Study of LY3039478 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
247 enrolled 53 charts
Lymphoid

Lymphoma, Neoplasm Metastasis, Neoplasms

NCT04726332 2024-05-14

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Exelixis

Phase 1 Terminated
52 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Neoplasms, Triple Negative Breast Neoplasms

NCT02380313 2016-10-06

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

GlaxoSmithKline

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT00399087 2014-02-13

Phase I Trial of Docetaxel With Perifosine

AEterna Zentaris

Phase 1 Completed
39 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡